Cargando…
HIV integrase variability and genetic barrier in antiretroviral naïve and experienced patients
BACKGROUND: HIV-1 integrase (IN) variability in treatment naïve patients with different HIV-1 subtypes is a major issue. In fact, the effect of previous exposure to antiretrovirals other than IN inhibitors (INI) on IN variability has not been satisfactorily defined. In addition, the genetic barrier...
Autores principales: | Piralla, Antonio, Paolucci, Stefania, Gulminetti, Roberto, Comolli, Giuditta, Baldanti, Fausto |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3077329/ https://www.ncbi.nlm.nih.gov/pubmed/21453487 http://dx.doi.org/10.1186/1743-422X-8-149 |
Ejemplares similares
-
EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count
por: Paolucci, Stefania, et al.
Publicado: (2021) -
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
por: Paolucci, Stefania, et al.
Publicado: (2012) -
HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland
por: Parczewski, Miłosz, et al.
Publicado: (2012) -
Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients
por: Paolucci, Stefania, et al.
Publicado: (2013) -
Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations
por: Paolucci, Stefania, et al.
Publicado: (2019)